Ovarian Development Articles & Analysis: Older
8 news found
TAG-72 a well-validated target, highly expressed on a range of adenocarcinomas including ovarian and gastric cancers. Issuance of the patent is an important milestone in underpinning the development of new treatments for these cancers. ...
” About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. ...
About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. ...
About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. ...
“As a patient-driven company, we at Sutro are extremely pleased that STRO-002— which we are presently developing in ovarian cancer—had a profound effect in a pediatric patient group with a rare form of AML, for which treatment options are limited,” said Bill Newell, Sutro’s Chief Executive Officer. ...
About Vivesto Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. ...
” About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. ...
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer — mesothelioma, and melanoma of the eye. ...